Capital winter
-
Boston’s Biotech Winter: The Industry’s Growing Pains from Hope to Anxiety—The Dilemma and Future of the Global Biotech Hub
DrugTimes will continue to follow and report on this key topic
-
Orelabrutinib’s revenue hits a new milestone! InnoCare Pharma is fully committed to crafting the second growth curve in autoimmune diseases
Welcome to watch InnoCare Pharma’s 2024 R&D Day!
-
In the midst of a market downturn, with a year-on-year sales increase of 50%, what did this biopharma do right?
A Biopharma with outstanding product innovation and internal adjustment capabilities has no reason not to navigate through the cycle
-
Just finished raising 200 million dollars, and then plan to lay off all the employees?
DrugTimes will continue to pay attention and report timely
-
Over 50% of Biotech Companies IPO on NASDAQ in 2024 Still Face Challenges
All comments are warmly welcome! Many thanks!
